Abstract: A novel receptor-type protein tyrosine phosphatase-.beta. (RPTP.beta.) protein or glycoprotein is disclosed. This protein is naturally expressed in the brain and in neural cell lines.

Abstract: A family of platinum complexes which are stable and exhibit anticancer activity.

Abstract: Monoclonal antibodies to the erythropoietin receptor are disclosed.

Abstract: A monoester compound of formula I:Nu--O--Fawherein O is oxygen, Nu is a nucleoside analog, Fa is an acyl group of a mono-unsaturated C18 or C20 omega-9 fatty acid, which fatty acid is esterified with a hydroxyl group in the 5'-position of the sugar moiety of the nucleoside analog or with a terminal hydroxyl group on the non-cyclic group of the nucleoside analog, and wherein Nu is represented by the formula II:B--Swherein S is a mono-saccharide derivative and B is a heterocyclic ring system.

Abstract: The present invention relates to 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosines having excellent antitumor activity, represented by formula [I]: ##STR1## wherein R represents a hydrogen atom or a phosphoric acid residue, and to a process for the production and use thereof.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.

Abstract: A manufacturing method for an ink jet head having an ink ejection pressure generation element for generating energy for ejecting ink, and an ink supply port for supplying the ink to an ink jet head, including the steps of preparing a silicon substrate; forming, on a surface of the silicon substrate, the ink ejection pressure generation element and silicon oxide film or silicon nitride film; forming anti-etching mask for forming an ink supply port on a back side of the silicon substrate; removing silicon on the back side of the silicon substrate at a position corresponding to the ink supply port portion through anisotropic etching; forming an ink ejection portion on a surface of the silicon substrate; and removing the silicon oxide film or silicon nitride film from the surface of the silicon substrate of the ink supply port portion.

Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: The present invention relates to improved methods for making and using-bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides and polyethers, and to the resulting compositions. The polymers are associated with each other, and are then either dried or are used as fluids. Bioresorbable, bioadhesive, anti-adhesion compositions are useful in surgery to prevent the formation of post-surgical adhesions. The compositions are designed to breakdown in-vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aqueous solutions. The anti-adhesion, bioadhesive, bioresorptive, antithrombogenic and physical properties of such membranes can be varied as needed by carefully adjusting the pH of the polymer casting solutions, polysaccharide composition, the polyether composition, or by conditioning the membranes prior to surgical use.

Abstract: Novel compositions comprised of at least one bead conjugated to a solid support and further conjugated to at least one nucleic acid and preferred methods for making the novel compositions are described. As compared to "flat" surfaces, beads linked to a solid support provide an increased surface area for immobilization of nucleic acids. Furthermore, by selecting a bead with the desired functionality, a practitioner can select a functionalization chemistry for immobilizing nucleic acids, which is different from the chemistry of the solid support.

Abstract: Disclosed herein are a modified epimorphin obtained by adding a hydrophilic peptide composed of 5 to 99 amino acids to at least one terminus of a polypeptide containing the functional domain of epimorphin, and a modified epimorphin composed of a polypeptide having a structure wherein a hydrophobic domain adjacent to the C-terminus of the whole-length epimorphin consisting of a coiled coil domain (1) on the N-terminal side, a functional domain (2) at the center, a coiled coil domain (3) on the C-terminal side and the hydrophobic domain (4) adjacent to the C-terminus has been deleted from the whole-length epimorphin, and at least part of amino acids have been deleted from the terminal side of at least one of the coiled coil domains (1) and (3) as well.

Abstract: Tyrosine sulfate on PSGL-1, particularly at least one of residues 46, 48 and 51, functions in conjunction with sialylated and fucosylated glycans, most preferably Thr-57, to mediate high affinity binding to P-selectin. PSGL-1 O-glycans have been determined to consist of disialylated or neutral forms of the core-2 tetrasaccharide Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.6(Gal.beta.1.fwdarw.3)GalNAcOH. A minority of the O-glycans are .alpha.1,3 fucosylated that occur as two major species containing the sialyl Lewis x antigen--one species is a disialylated monofucosylated glycan:Fuc.alpha.1 .dwnarw. 3 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1 .dwnarw. 6 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.3GalNAc-R,and the other is a monosialylated, trifucosylated glycan having a polylactosamine backbone:Fuc.alpha.l .dwnarw. 3 NeuAc.alpha.2.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1. fwdarw. Fuc.alpha.l Fuc.alpha.l .dwnarw. .dwnarw. 3 3 4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1 .

Abstract: This invention is a method and composition for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amount of an ester of probucol.

Abstract: A lavage solution for intestinal tract which is easily applied in a treatment conducted prior to endoscopy of the intestines, surgery of the intestines and the like and hardly generates foam upon actual use and is stable as a pharmaceutical preparation is disclosed. The lavage solution for intestinal tract is an emulsified liquid mainly consisting of water-soluble high-molecular compound and electrolyte and an antifoaming agent of a silicone type.

Abstract: The invention provides new methods for synthesizing oligonucleotides containing at least one, and preferably all phosphorodithioate internucleoside linkages with less than 5% phosphoromonothioate contamination. This level of purity in the synthesis of phosphorodithoates has previously been very difficult to achieve with all existing methods. The invention further provides phosphorothioamidite nucleoside synthons comprising a sulfur protecting group that is stable under normal oligonucleotide synthesis conditions.

Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a combination of compounds selected from the group consisting of hydroxyurea, a nucleoside analog, and a protease inhibitor.

Abstract: Described are methods of detecting G-protein coupled receptor (GPCR) activity in vivo and in vitro; methods of assaying GPCR activity; and methods of screening for GPCR ligands, G Protein-coupled receptor kinase (GRK) activity, and compounds that interact with components of the GPCR regulatory process. Constructs useful in such methods are described.

Abstract: The present invention provides a metalloporphyrin catalyst represented by the structure: ##STR1##

Abstract: The invention relates to compositions comprising acyl derivatives of 2'-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tissue repair, comprising administering the compositions of the present invention to an animal.

Abstract: The invention relates generally to compositions of and methods for obtaining mu opioid receptor polypeptides. The invention relates as well to polynucleotides encoding mu opioid receptor polypeptides, the recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, recombinant opioid receptor polypeptides, and antibodies immunoreactive with mu opioid receptors. The invention includes as well, methods for using the isolated, recombinant receptor polypeptide in assays designed to select and improve substances capable of interacting with mu opioid receptor polypeptides for use in diagnostic, drug design and therapeutic applications.